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ABSTRACT 
 
Methyl-CpG binding domain (MBD) proteins are considered as the epigenetic readers of the 
methyl tags on DNA. This highly conserved family of DNA-binding proteins recognizes the 
information represented by methylation patterns and transduces them into appropriate functional 
states. MBD proteins bind to the DNA around methylated cytosine bases located particularly in 
the promoter regions, preventing binding of transcription factors and RNA polymerase and 
thereby repress transcription. Region-specific DNA hypermethylation is considered as a critical 
factor in tumorigenic progression. This hypermethylation induced silencing of tumor suppressor 
genes in cancer cells is mediated by MBD proteins, hence they are now considered as potential 
biomarkers for diagnosis and prognosis of malignant transformation. The present study will be 
conducted to analyse the gene expression status of the methyl-CpG-binding (MBD) proteins - 
MeCP2, MBD1, MBD2, MBD3 and MBD4 in breast cancer. This study will help in creating an 
epigenetic signature based on MBD protein distribution and occupancy in a gene and tumor type 
specific context for diagnosis and detection of different cancer types. 
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INTRODUCTION 
 
Gene expression is a function of multiple factors which act in a coordinated and 
synchronized manner to direct efficient cellular homeostasis. The physiological template of all 
eukaryotic information, the chromatin is subjected to numerous modulations of its components, 
the histones and the DNA. These manipulations effectively modulate the gene expression profile 
and subsequently affect the functional destiny of a cell. The complete set of such modifications 
constitute the epigenome which brings about differential gene expression without changing the 
underlying DNA sequence. Epigenetic modifications are mitotically or meiotically heritable 
changes that allow a remarkably stable propagation of gene activity states over many cell 
generations. The principal epigenetic signals include DNA methylation post-translational 
reversible modifications of the histone such as acetylation, methylation, phosphorylation and 
gene silencing mediated by non-coding RNAs. There exists a harmonious and homeostatic 
balance between the various epigenetic manipulations so as to preserve the integrity of the 
genetic message across several generations yet culminate in functional specialization in cell and 
tissue-specific manner. 
DNA methylation is the most investigated epigenetic factor facilitating effective cell-
specific gene repression. It is now considered as one of the first steps in epigenetic regulation 
acting as a fundamental mechanism in functional organization of the human genome. It 
assimilates the previously established repression marks via histone modifications to permanently 
turn off unnecessary genes during development. Methylation of DNA is a post-synthetic process 
catalyzed by a family of dedicated enzymes known as DNMTs (DNA methyltransferases) -- 
DNMT1, DNMT3A and DNMT3B that methylate the cytosine residue specifically at CpG rich 
promoter sequences in the presence of cofactor SAM (S-Adenosyl methionine). These 
methylated cytosine residues are recognized and the information represented by the methylation 
patterns is transduced into appropriate functional states by Methyl-CpG binding domain (MBD) 
proteins which are considered as the epigenetic readers of the methyl tags on DNA. MBD 
proteins bind to the DNA around methylated cytosine bases located particularly in the promoter 
regions, preventing binding of transcription factors and RNA polymerase and thereby repress 
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transcription. Secondly, association of MBD proteins with methylated DNA induces recruitment 
of HDACs (Histone Deacetylases) resulting in heterochromatin formation and transcriptional 
inactivation. 
An altered pattern of gene expression resulting in aberrant gene function is a key feature 
of malignant transformation. Proliferation and propagation of cancer involves coordinated 
changes in gene expression program of multitude of genes. Since genomic information is edited 
in accordance with the epigenetic instruction manual, it is thus plausible that changes in the 
status of epigenome aids in oncogenic development. Epigenetic and genetic mechanisms may 
thus work in tandem to silence the transcription of key cellular genes and destabilize the genome, 
leading to malignant transformation and tumorigenesis. Gene-specific regional hypermethylation 
and subsequent silencing of tumor suppressor genes is considered as a principle feature in 
tumorigenic progression. This hypermethylation induced silencing of tumor suppressor genes in 
cancer cells is mediated by MBD proteins, hence they are now considered as potential 
biomarkers for diagnosis and prognosis of malignant transformation. In the light of the functional 
significance of the MBD proteins in the epigenomic landscape, the present study was designed to 
investigate the gene expression pattern and profiling of this family of MBD proteins - MeCP2, 
MBD1, MBD2, MBD3 and MBD4 in breast cancer. A comparative analysis of the expression 
levels of different MBD proteins after treatment with epigenetic drug AZA (5’-Aza-2-
deoxycytidine) and modulator SAM (S-adenosyl methionine) will be done to create a diagnostic 
profile in breast cancer. The project aims to provide a comprehensive knowledge about the gene 
expression of the MBD proteins in breast cancer samples so as to create a distinct epigenetic 
biomarker for effective prognosis in breast cancer. This study will help in creating an epigenetic 
signature based on MBD protein distribution and occupancy in a gene and tumor type specific 
context for diagnosis and detection. Further studies in a variety of different cancer tissues will 
provide an exhaustive idea regarding the role of MBD proteins in malignant transformation and 
subsequently result in an epigenetic signature for efficient molecular detection strategies. 
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REVIEW OF LITERATURE 
 
Epigenetics is the study of mitotically or meiotically heritable changes in gene function 
without changes in the underlying DNA sequence. The primary molecular epigenetic 
mechanisms responsible for regulation of chromatin structure and gene expression are DNA 
methylation, histone modifications, nucleosome positioning and non-coding RNAs (Sharma et 
al., 2010). In modern biology, the concept of epigenetics originally referred to developmental 
phenomena, but, more recently, it has come to signify a functional aspect of gene action, whereas 
epigenetic inheritance signifies modulation of gene expression without modifying the DNA 
sequence (LeBaron et al., 2010). Epigenetic modifications are heritable, reversible covalent 
modifications that work in tandem to orchestrate the transcriptional activity of the genome in 
various biological settings. 
 
 
 
Epigenetic mechanisms are heritable changes in gene expression patterns that result in cell and tissue 
specific functional specialization. Shown above are the two main components of this regulatory 
system- DNA methylation and Histone Modification.   
(Adapted from Qiu, 2006, Nature) 
Figure 1: Epigenetic Regulatory Mechanisms. 
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DNA Methylation-The Principal Epigenetic Modulator of Gene Expression: 
 
The addition of methyl group (CH3) at 5
’
-position of cytosine is called DNA Methylation. DNA 
methylation is the chief epigenetic modification of the genome that affects basic biological 
functions, like gene expression and cell development. DNA methylation has key role in normal 
development and cellular differentiation in higher organisms. In vertebrates, 3-6% of DNA 
cytosine is methylated, but this percentage decreases down the evolutionary levels, so that in 
many insects and single-celled eukaryotes there is no noticeable 5-methylcytosine (Adams & 
Burdon, 1985). DNA methylation generally occurs in a CpG dinucleotide in somatic tissues. 
DNA methylation is catalyzed by a family of enzymes known as DNA methyltransferases 
(DNMTs) consisting of DNMT1, DNMT3A, and DNMT3B. DNA methylation also plays a 
crucial role in the development of nearly all types of cancer. The main functions of methylation 
in the eukaryotic genome entails regulation of gene expression, chromatin compaction via 
heterochromatin formation, X-chromosome inactivation, maintaining genome stability and 
maintaining cellular identity (Robertson, 2002). 
 
 
 
DNA methylation is a post-synthetic process of covalent addition of a methyl group in the C5 
position of cytosine residues in the DNA catalyzed in presence of co-factor SAM (S-Adenosyl 
Methionine),(which gets converted to SAH (S-Adenosyl Homocysteine)) by a family of enzymes 
known as DNA methyltransferases (DNMT). 
(Adopted from Zhou and Lu, 2008, Journal of Autoimmunity). 
Figure 2: DNA (Cytosine)-methylation reaction catalyzed by DNMTs. 
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DNA methylation is naturally removed during zygote formation and re-established through 
successive cell divisions during development although the latest research shows that 
hydroxylation of methyl group occurs rather than complete removal of methyl groups in zygote. 
In zygote development just after fertilization, the parental DNA experiences drastic loss of DNA-
methylation before the zygote starts dividing i.e. before its DNA is replicated (Patra et al., 2002). 
The DNA mediated gene silencing is mediated and controlled by the presence of some proteins 
like MBD proteins. The MBD family of proteins consists of five members: MeCP2, MBD1, 
MBD2, MBD3 and MBD4 (Berger and Bird, 2005).  Each of these proteins, with the exception 
of MBD3, is able to binding specifically to methylated DNA. MECP2, MBD1 and MBD2 can 
also repress transcription from methylated gene promoters.  
 
 
 
 
 
Promoters containing methylated CpG sites directly inhibit gene transcription by blocking the 
binding of transcription factors (TF) to the promoter regions (A). The formation of heterochromatin 
(closed chromatin) associated with methylated DNA and deacetylated histones may prevent the 
access for transcription factors from binding to DNA (B). The silencing of a gene may also result 
from the binding of methyl-binding proteins (e.g. MePC2) to the methylated cytosine which recruits 
Histone Deacetylases (HDAC) leading to non-permissive chromatin state that ultimately prevent a 
TF to bind its target promoter (C). 
(Adopted from Vaissiere et al., 2008, Mutation Research). 
Figure 3: Mechanisms for gene silencing mediated by DNA methylation. 
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MBD1 (Methyl-CpG-binding domain protein 1): 
MBD1 is also termed as CXXC3, PCM1, RFT. These proteins are able to bind specifically to 
methylated DNA and repress transcription in methylated gene promoters (Patra et al., 2001). The 
MBD1 is highly expressed in brain, heart, kidney, lung, skeletal muscle, spleen and testis. 
Human MBD1 contains 645aa whereas the mouse MBD1 is made up of 713aa and the sequence 
identity between them is 66.8% (Roloff et al., 2003). MBD1 occurs in five isoforms which are 
produced by alternative splicing in the cystine-rich CXXC and C-terminal domains. These five 
isoforms also have the ability to repress transcription in methylated promoters, and MBD1v1 and 
MBD1v2, which contain three CXXC domains each, also repress transcription in unmethylated 
promoters (Fujita et al. 2000).  
MBD2 (Methyl-CpG-binding domain protein 2): 
MBD2 is also known as the DMTase or Demethylase. MBD2 protein functions as a demethylase 
to activate the transcriptional machinery and can also act as a transcriptional repressor like 
MBD1 on the basis of presence of interacting partners. MBD2 shows 71.1% overall amino acid 
identity to MBD3 (Hendrich and Bird, 1998). MBD2 in humans contain 478aa whereas in mouse 
contains 454aa and the sequence identity between them is 93.2% (Roloff et al., 2003). Location 
of MBD2 is at 18q21. MBD2 occurs in two isoforms- Mbd2a and Mbd2b produced by 
alternative splicing.  
MBD3 (Methyl-CpG-binding domain protein 3): 
MBD3 acts as transcriptional repressor and plays a role in gene silencing. MBD3 is highly 
expressed in brain, heart, kidney, skeletal muscle, spleen, liver, lung, testis, ES cells. Human 
MBD3 contain 331aa whereas mouse contains 362aa and the identity between them is 85.1% 
(Patra et al., 2003). 
MBD4 (Methyl-CpG-binding domain protein 4): 
MBD4 is also known as MED1. It acts as a transcriptional repressor and is also involved in DNA 
repair due to the presence of glycosylase domain. It is highly express in the brain, spleen and 
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testis. The human MBD4 contain 647aa where in mouse 631aa and between them 63.8% 
identity. 
MeCP2 (Methyl CpG Binding Protein 2): 
It is highly expressed in. brain, heart, liver, lung, kidney, skeletal muscle, placenta and pancreas. 
MeCP2 gene mutation is the cause of most cases of Rett syndrome. MeCP2 can repress 
transcription in methylated gene promoter as like in MBD1 and MBD2. 
 
. 
All MBD family members contain a methyl binding domain which helps in the interaction between 
the methylated cytosine residue in the DNA and the protein active site. The MBD sequence motif is 
depicted as an orange box in each protein. The CxxC domain help in interaction with DNMTs and 
the TRD domain is the interface that acts to silence the gene transcriptional machinery. 
Abbreviations: MBD, Methyl-Binding Domain; TRD, Transcription Repression Domain; GR, 
alternating Glycine and Arginine repeats. 
 (Adopted from Fatemi and Wade, 2006, Journal of Cell Science). 
Figure 4: Characteristic structural domains of the methyl CpG binding protein family. 
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MBD Proteins act on Gene Silencing and Transcriptional Inactivation: 
In mammalian cells, DNA methylation is linked with heritable and stable gene repression 
mediated in part by methyl-CpG-binding domain (MBD) proteins that interact with corepressors 
to change chromatin structure (Patra et al., 2002). MeCP2 is a universal transcriptional repressor 
by silencing the gene. It can bind to a single methylated CpG and take on the Sin3A repressor 
complex to silence transcription via histone deacetylation. MeCP2 seems to bind theSin3A 
repressor complex, which acts to remodel chromatin into a state refractory to transcription via 
the recruitment of HDACs (Nan et al., 1998). These data and the fact that MeCP2 binds to a 
single symmetrically methylated CpG pair (which are widespread in the genome) implies that 
MeCP2 is a universal transcriptional repressor in vivo (Patra et al., 2003). MBD1 is concerned 
with methylation-mediated repression of genes whose promoters carry CpG islands resulting in 
heterochromatin formation and gene silencing in vertebrates (Fujita et al., 2000). MBD1 have 4 
novel isoforms i.e. MBD1v1, MBD1v2, MBD1v3, and MBD1v4 and all isoforms can inhibit 
promoter activities of genes by methylation (Fujita et al., 1999). MBD1 protein forms a complex 
with   SETDB1 histone methyltransferase to silence transcription at target promoters by   
methylation   of   lysine   9   of   histone   H3 (Lyst et al., 2006; Sarraf and Stancheva, 2004).  
MBD2 mediates the methylated DNA binding functions for 2 dissimilar transcriptional 
repressor complexes, MECP1 and Mi2/NuRD (Jin S. et al., 2005). Both these complexes utilize 
MBD2 to direct HDACs and chromatin remodelers to methylated promoters, where they result in 
transcriptional repression. MBD2 is the methyl-binding component of the MeCP1 complex, 
which also contains the histone deacetylase (HDAC) proteins HDAC1, HDAC2 and allowing 
MBD2 to target HDAC/chromatin remodeling action to methylated templates (Patra et al., 
2003).. MBD2 can also associate with MBD3, which is component of the Mi2/NuRD co-
repressor complex. MBD2 and MBD3 can form a complex with DNMT1 on hemimethylated 
DNA at replication foci, which might help to keep the repressive transcription state after 
replication. MBD3 shares significant DNA and protein sequence homology to MBD2, and is a 
part of the Mi2/NuRD chromatin-remodelling complex. The binding properties of MBD3 are 
different between species: mammalian MBD3 does not bind methylated DNA (Hendrich and 
Bird, 1998) whereas Xenopus MBD3 binds strongly to methylated DNA. MBD4 plays a key role 
in maintaining methylated DNA gene regulation and suppressing mutations at CpG sites. MBD4 
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is different from other MBD proteins because its interactions with the DNA repair machinery. 
The protein uses its N-terminal MBD to bind methylated CpG and its C-terminal glycosylase  to 
mediate repair of CpGs, which is susceptible to mismatch formation following either the 
hydrolytic deamination of 5-methylcytosine to thymine or deamination of cytosine to uracil. 
 
 
 
 
The different members of the MBD proteins interact with different protein partners such as Histone 
Methyltransferases (SETDB1, Suv39h1), Chromatin Remodelling Complexes (Sin 3A/Mi-NuRD 
complex) and Histone Deacetylases (HDAC1, HDAC2) to  
mediate transcriptional silencing and gene activation.  
(Adapted from Lopez-Serra and Esteller, 2008, British Journal of Cancer). 
Figure 5: Mechanism of epigenetic gene silencing by MBD Proteins. 
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Regional hypermethylation induced gene silencing is a basic mechanism in gene silencing during 
cancer. MBD proteins play a vital role in tumorigenic progression as they bind to hypermethylated 
promoters of tumor suppressor genes, cell cycle regulatory genes and prevent their function. While 
MBD1, MBD2, MBD3 and MeCP2 mainly silence methylated promoters by binding to them, MBD4 
mediated hypomethylation of oncogenes is the causative factor in malignant transformation.  
(Adapted from Parry and Clarke, 2011, Genes and Cancer). 
Figure 6: Mechanisms of MBD protein mediated gene silencing in cancer. 
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OBJECTIVES OF THE PROJECT 
 
1. Study of the gene expression status of the different MBD proteins - MeCP2, MBD1, 
MBD2, MBD3 and MBD4 in MDA-MB-231 breast cancer cell line. 
 
2. Study of the effect of various epigenetic modulators such as 5’-Aza-2’-deoxycytidine 
(AZA) and S-Adenosyl homocysteine (SAM) on the expression of the different MBD 
genes after 24 hours treatment at the transcriptome level. 
 
3. Comparative analysis of the effect of the various epigenetic modulators on the 
different MBD proteins and on the survival of MDA-MB-231 breast cancer cells. 
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MATERIALS AND METHODS 
 
1. In vitro cell culture: 
MDA-MB-231 human mammary tumor cells were cultured and maintained in DMEM 
(Dulbecco’s Modified Eagle’s Medium) supplemented with 10% (v/v) FBS (Fetal Bovine 
Serum) and 100 IU/mL Penicillin & 0.1 mg/mL streptomycin in a humified atmosphere of 5% 
CO2 at 37 °C. 
 
2. Drug treatment with AZA and SAM: 
The cells (3 × 10
5
/well) were grown in 6-well plates (40–50% confluent) and then treated with 
AZA (5,7,10,15,20,25,50,75,100 μM conc.) and SAM (5,7,10,15,20,25,50,75,100 μM conc.) 
mixed in DMEM supplemented with 5% FBS to determine the optimum doses for the drugs. 
Cells were then incubated at 37 ◦C in complete growth medium for 24 and 48 hrs. Control cells 
were treated identically, except that no drugs were added to the cell medium. 
 
3. Cell Viability Analysis by colometric MTT Assay: 
Cell viability analysis and cytotoxicity studies were performed using the MTT assay based on the 
observation that the mitochondria in living cells can catalyze MTT molecules to a 
colorimetrically detectable dye. The drug-treated cells were washed in PBS, trypsinized and then 
seeded in 96-well plate at 10
5
 cells/well (200 μl).100 μl of MTT solution (0.8 mg/ml) was then 
added to each well and the cells were incubated at  37º C  for 4 hrs. Thereafter, DMSO was 
added to all wells and mixed thoroughly to dissolve the dark blue precipitate and incubated for 
15 mins at room temperature. The absorbance of samples was determined at a wavelength of 590 
nm. The extent of cytotoxicity was defined as the relative reduction of the optical density (OD), 
which correlated to the amount of viable cells in relation to cell control (100%). The cell 
viability was plotted in a graph and the IC50 was calculated accordingly to decide the optimum 
dosage of the drugs for further studies. The results were presented as mean ±S.D. (n = 3) 
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4. Flow Cytometry Analysis of the effects of epigenetic drugs on cell cycle (FACS): 
Flow cytometry analysis of PI stained nuclei was done to assess the effects of epigenetic drugs 
AZA and SAM on the cell cycle distribution. AZA (10 and 15 μM) and SAM (10 and 20 μM) 
treated cells were incubated in DMEM with 5% FBS for 24 and 48 hrs. The cells were then 
trypsinized, collected by centrifugation, washed twice with PBS and then fixed in 90% ice-cold 
methanol. After incubation at -20℃ for 1 hr, cells were centrifuged and resuspended in PBS 
followed by treatment with RNaseA (500 U/ml) to digest the residual RNAs and stained with 
propidium iodide (50 ng/ml). Samples were incubated for 30 min at room temperature and cell 
cycle analysis was performed with a Becton–Dickinson fluorescence-activated cell sorter 
(FACS). 
 
5. Chromatin condensation analysis after 24 hours drug treatment by Hoechst staining: 
After treatment with drugs, the cells were stained with Hoechst 33342 stain (1 μg/ml) and 
incubated for 10 min at 37ºC and images were taken under UV filter using Epi-fluorescene 
Microscope at 400 X magnification with an excitation wavelength of 355-366 nm and an 
emission wavelength of 465-480 nm. 
 
6. Extraction of Total RNA: 
Total RNA was extracted from MDA-MB 231 cells by using the Trizol reagent. The drug treated 
cells (5-10 X 10
6
 cells) were washed with 1 ml ice cold PBS, then trypsinized and then treated 
with 1 ml Trizol. 0.2 ml of chloroform (0.2 ml per 1 ml of TRI Reagent) was added to the tubes, 
shaken vigorously for 30 seconds by hand/vortex mixer and incubated at RT for 10 mins. The 
samples were centrifuged at 12,000 X g for 15 mins at 4 ° C. Following centrifugation, the 
mixture separates into lower red, phenol-chloroform phase, an interphase, and a colorless upper 
aqueous phase containing the RNA.  The upper aqueous phase was removed without disturbing 
the interphase and collected in a fresh tube.  0.5 ml isopropyl alcohol per 1 ml of TRI Reagent 
was added to the tubes. The tubes were then incubated at RT for 10 minutes and then centrifuged 
at not more than 12,000 x g for 10 minutes at 4 ° C. The supernatant was removed completely. 
The RNA precipitate, often invisible before centrifugation, forms a gel-like pellet on the side and 
bottom of the tube. The pellet was washed with 1ml of 75% ethanol per 1 ml of TRI Reagent. 
The samples were mixed by vortexing and centrifuged at no more than 7,500 x g for 5 minutes at 
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4 ° C.  The pellet was air-dried by keeping the RNA pellet containing tube opened in working 
bench for 15 mins. The RNA was dissolved in50 μl EPC-treated water by passing solution a few 
times through a pipette tip. The RNA was stored at - 20° C for further use or immediately 
processed for cDNA synthesis. 
 
7. Quantitative Estimation of RNA Concentration by Spectrophotometric Analysis: 
The concentration of the extracted total RNA was quantified by measuring the absorbance at 260 
nm in a spectrophotometer (ELICO, BL 200 Bio Spectrophotometer, double beam) and 
calculated by using the formula as given below: 
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
 
8. Quantitative Estimation of RNA Concentration by Denaturing Gel   Electrophoresis: 
The extracted RNA was run on a denaturing agarose gel and the quantity of RNA estimated from 
the band intensity. For denaturation gel (40 ml), 0.6 g agarose (Sigma), 28.8 ml dH2O (Sigma), 
7.2 ml formaldehyde (Sigma), 4 ml 10X MOPS buffer were mixed properly. About 2 μl (2μg) of 
the total RNA was mixed with 18 μl 1X Reaction Buffer (2μl of 10X MOPS Buffer, 4 μl 
formaldehyde, 10 μl formamide (Sigma) ,2 μl 0.2 mg/ml Etbr (Sigma)) and incubated at 55 °C 
for 1 hr. It was then cooled on ice and loaded in the wells of the denaturing gel. 
 
9. First strand cDNA synthesis: 
Total RNA (4 g) was used for first strand cDNA synthesis by reverse transcription using 
RevertAid
TM 
First Strand cDNA Synthesis Kit (Fermentas) in a thermocycler (Biorad). The RNA 
was incubated with 1 l of oligo (dT)18  primers (100 μM, 0.2 μg/μl) and 12 μl of nuclease-free 
water at 65 C for 5 min. The reaction was cooled on ice to allow the primers to anneal to the 
RNA, then spin down and placed on ice again after which the following components were added 
to the reaction in order; 4 l of 5X Reaction Buffer, 1 l of RibolockTM RNase inhibitor (20 
U/l), 2 l of 10 mM dNTPs and 1.0 L of RevertAidTM M-MuLV-Reverse Transcriptase (200 
U/l). The reagents were gently mixed and incubated for 1 hr at 42C. Heating at 70C for 5 min 
terminated the reaction and the synthesized cDNA was stored at –20 0 C for further use. 
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10. Gene-specific semi-quantitative PCR for amplification of the desired genes: 
 
The PCR reaction mixtures, in a 25 μl volume, contained 17 μl of dH2O (Sigma), 2.5 μl of 1X 
PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, Sigma), 0.5 μl 
each of the forward and reverse primers (0.2 μM, Sigma) of MBD1, MBD2, MBD3, MBD4, 
MeCP2 and 0.5 μl Taq DNA-polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was 
added. PCR amplifications of MBD1, MBD2, MBD3 and MBD4 were performed in a thermal 
cycler (Biorad) by initial denaturation at 94° C for 1 min, followed by 30 cycles of denaturation 
at 94° C for 20 secs, annealing at 57 ° C for 20 secs, and extension at 72° C for 30 secs, followed 
by an final extension step at 72° C for 5 mins. The constitutively expressed housekeeping gene, 
β-actin was used as a positive control to ensure high quality. RT-PCR products were then 
analyzed by 1% agarose gel electrophoresis containing ethidium bromide (0.05%). The primer 
sequences used for the PCR reaction are shown in Table 1.  
 
Table 1.Table showing the forward and backward primers and their amplicon sizes. 
 
 
 
 
PRIMER 
 
 
 
 
TYPE 
 
 
 
 
SEQUENCE 
   Table 1.Table showing t he sequence of the forward and bac kward primers.  
 
 
 
 
AMPLICON (bp) 
 
 
 
MBD1 
 
 
Forward 
 
 
 
5’  CCTGGGTGCTGTGAGAACTGT   3’ 
107  
           
 
 
 
 
 
 
 
 
 
                                                                                                             107   
Reverse 
 
 
 
5’  TTGAAGGCAATTCTCTGTGCTC   3’ 
 
 
 
MBD2 
 
 
 
Forward 
 
 
 
 
5’ AGGTAGCAATGATGAGACCCTTTTA   3’ 
                   
 
 
 
 
 
    
 
 
 
 
 
 
 
             116  
 
Reverse 
 
 
 
5’  TAAGCCAAACAGCAGGGTTCTT   3’ 
 
MBD3 
 
 
 
Forward 
 
 
 
 
5’  CCGCTCTCCTTCAGTAAATGTAAC  3’ 
          
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                             101  
 
Reverse 
 
 
 
 
5’  GGCTGGAGTTTGGTTTTCAGAA   3’ 
 
MBD4 
 
 
 
Forward 
 
 
 
 
5’  AGACCCGCCGAATGACCT   3’ 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
                               144  
 
 
Reverse 
 
 
5’  GCACCAAACTGAGCAGAAGCG   3’ 
 
MeCP2 
 
 
 
Forward 
 
 
 
 
5’  TGACCGGGGACCCATGTAT   3’ 
          
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                        145  
 
Reverse 
 
 
 
 
5’  CTCCACTTTAGAGCGAAAGGC   3’ 
 
β-ACTIN 
 
 
 
Forward 
 
 
 
 
5’   CTGGAACGGTGAAGGTGACA  3’ 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                           140   
Reverse 
 
 
 
5’   AAGGGACTTCCTGTAACAACGCA   3’ 
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11. Relative Gene Expression Analysis after drug treatment by Real-Time PCR: 
Quantitative estimation of the expression of the MBD genes after drug treatment was done via real-time 
PCR analysis. cDNA was used to analyze the expression of MBD genes along with β-Actin as a house 
keeping gene. 
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RESULTS AND DISCUSSION 
 
1. Cell Viability Analyses by colometric MTT Assay: 
Cytotoxicity studies were performed to determine the effect of epigenetic drugs such as AZA 
(inhibitor of DNMT) and SAM (co-factor in the methylation reaction) on the expression of MBD 
genes. In order to determine the optimum dosage, different concentrations of the drugs were 
considered and the treatment was done for different time intervals. The results obtained from the 
MTT assays are given below: 
 
(A) 
 
(B) 
Figure 7: The effect of different concentrations of drug AZA (5, 7,10,15,20,25,50,75,100 μM) 
at different time intervals of 24 hrs (A) and 48 hrs (B) on the survival of MDA-MB-231 breast 
cancer cells.  
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(A) 
 
(B) 
 
Figure 8: The effect of different concentrations of drug SAM (5, 7,10,15,20,25,50,75,100 μM) at 
different time intervals of 24 hrs (A) and 48 hrs (B) on the survival of MDA-MB-231 breast 
cancer cells.  
In general, cell survival levels declined progressively with an increased dose of both the 
epigenetic drugs (Fig 7 & 8). While treatment with increasing doses of AZA showed a drastic 
decline in cell survival, SAM showed comparatively lesser toxicity. From this assay, 15 μM of 
AZA and 20 μM of SAM were chosen as the optimum doses for MBD expression studies. 
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2. Flow Cytometry Analysis of the effects of epigenetic drugs on cell cycle (FACS): 
Flow Cytometric analysis was done to assess the effect of the epigenetic drugs on the cell cycle 
and consequently co-relate these effects to cancer progression. AZA is a well-known inhibitor of 
DNMT1 and SAM is a co-factor in the methylation reaction. The results of the FACS study are 
represented below (Fig 9 & 10). As shown below, breast cancer cells were arrested in different 
phases in a dose and time dependent manner. In comparison to control, cells treated with AZA 
and SAM, showed increase in G1-phase cells, decreased percentage of S and G2 population as 
well as increase in apoptotic cells. Thus, the epigenetic modulators AZA and SAM induce 
differentiation, growth arrest and apoptosis in MDA-MB-231 cells. 
 
  
(A)                                                                           (B) 
Figure 9: Cell cycle distribution of MDA-MB-231 cells after treatment by two different doses of 
AZA (10 and 15 μM) for different time intervals of 24 hrs (A) and 48 hrs (B).  
The alterations in the cell cycle distributions were distinct at different time intervals (24 & 48 
hrs) as well as at low versus high doses. At a low dose of AZA (10 μM), there is an increase in 
G1 phase cells, decrease in S and G2 populations as well as in apoptotic cell percentage w.r.t to 
control. At higher dosage (15 μM), there is a drastic decrease in G1, S, G2 populations while 
apoptotic cell population increases. However, when the treatment is done for 48 hrs, there is a 
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increase in G2 phase cells w.r.t control. In summary, cells progressed from G1 to S phase at low 
dose treatment for 24 hrs, however after 48 hr treatment; there is growth arrest and apoptosis.  
   
(A)                                                                           (B) 
Figure 10: Cell cycle distribution of MDA-MB-231 cells after treatment by two different doses 
of SAM (10 and 20 μM) for different time intervals of 24 hrs (A) and 48 hrs (B). 
At a low dose of SAM (10 μM) for 24 hrs, there is an increase in G1 phase cells, S and G2 
populations and decrease in apoptotic cell percentage w.r.t control cells. However, when the 
treatment was done for 48 hrs, there is decrease in G1, S and G2 populations while apoptosis is 
greatly elevated. Thus, at low dosage, the cells progress through the different stages, but upon 
longer treatment show growth arrest. At a high concentration of SAM (20 μM), there is an 
decrease in G1 phase cells, S and G2 populations and increase in apoptotic cell percentage w.r.t 
control cells. After treatment for 48 hrs, the apoptotic cell population greatly increased along 
with G2 cells. Thus, the effect of SAM on the cell cycle progress gradually increases with 
increasing dosage and time interval, indicating a proportional relation with them. MBD proteins 
are known to interact with DNMTs and chromatin remodeling complexes to repress 
transcriptional activity via heterochromatin formation. As the DNMT modulators effectively 
disrupt the activity of DNMTs, there is a possibility that the action of MBD proteins can be 
interrupted.  
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3. Chromatin condensation analysis after drug treatment by Hoechst staining: 
Nuclear chromatin condensation in drug treated MDA-MB-231 cell by Hoechst staining is a 
visually detectable assay to quantify the amount of apoptotic cells after drug treatment. The blue-
fluorescent Hoechst 33342 brightly stains the condensed chromatin of apoptotic cells and less 
brightly stains the normal chromatin of live cells (Fig 11 & 12). After FACS analysis, the drug 
treated cells were stained with Hoechst dye to estimate the effectiveness of each drug and the 
rate of apoptosis inflicted by each drug. The results of the Hoechst staining assay are given 
below: 
 
(A)                                               (B)                                          (C) 
Fig. 11: Nuclear chromatin condensation in AZA treated MDA-MB-231 cell after 24 & 48 hrs. 
 
                    (A)                                              (B)                                              (C) 
 
Fig. 12: Nuclear chromatin condensation in SAM treated MDA-MB-231 cell after 24 & 48 hrs. 
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4. Relative Gene Expression Analysis after drug treatment by RT-PCR: 
In general, there is over-expression of all the MBD genes. MBD3 is known to interact with 
DNMT1, hence shows a comparatively reduced expression when treated with AZA and SAM 
than the other genes. MBD2 is mainly involved in DNA repair; hence its expression is mostly 
uniform upon treatment with various epigenetic drugs. 
 
Figure 13: Relative expression of the different MBD genes with respect to β-actin in AZA 
treated MDA-MB 231 cells. 
 
Figure 14: Relative expression of the different MBD genes with respect to β-actin in SAM 
treated MDA-MB 231 cells. 
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CONCLUSION 
 
In this study, we have shown the effect of different epigenetic modulators such as AZA and 
SAM on the expression of different members of the MBD group of proteins. MBD proteins 
interact with DNMT1 and chromatin remodeling complexes to bind to the methylated cytosine 
bases in CpG islands of the hypermethylated promoter regions and inhibit transcriptional 
activity. Hence it can be safely assumed that inhibiting MBDs can provide a means of negating 
its effect on transcriptional activity. Hence, inhibiting the DNMTs by DNMT inhibitors like 
AZA will serve as a means to restrict MBD proteins and help in transcriptional reactivation of 
silenced genes such as tumor suppressors, cell cycle regulatory and apoptosis inducing genes. 
The turning on of crucial tumor suppressor genes may be an efficient means to counteract 
malignant transformation; hence MBD proteins can be regarded as novel prognostic targets for 
cancer therapy. 
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